Lasa Supergenerics expands manufacturing capacity of API Albendazole

25 Apr 2025 Evaluate

Lasa Supergenerics has expanded its manufacturing capacity for Albendazole USP. This enhancement was achieved through strategic debottlenecking of existing infrastructure and the installation of new machinery at its manufacturing facility.

This expansion strengthens the company’s ability to meet increasing demand for Albendazole across domestic and international markets, reaffirming its position as a trusted supplier of highquality Active Pharmaceutical Ingredients (APIs), The Expansion will further achieve Increased Capacity of Albendazole USP, Improve Product Efficiency and reduce lead time, enhance global supply capacity with adherence to top-tier quality and standards.

With the said Expansion the Total capacity is anticipated to represent a growth of 20%. This expansion is supported by a capital investment (CAPEX) of nearly Rs 1 crore which is already deployed and additional will be deployed over the time.

Lasa Supergenerics is specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India.


Lasa Supergenerics Share Price

9.90 -0.10 (-1.00%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×